STING1 and lymphoma: In this open-label, multicenter, multicohort dose escalation phase I study, repeated IT injection and systemic SC injection of MK-2118, a noncyclic dinucleotide STING agonist, with or without pembrolizumab, demonstrated feasibility with a manageable safety profile in participants with advanced solid tumors or lymphomas.